Immune response hinders therapy for lysosomal storage diseases

Journal of Clinical Investigation

Volumn 118, Issue 8, 2008, Pages 2686-2689

  Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; AZATHIOPRINE; CYCLOSPORIN A; ENZYME ANTIBODY; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; IDURONATE 2 SULFATASE; LARONIDASE; LEVO IDURONIDASE; LEVO IDURONIDASE ANTIBODY; MANNOSE 6 PHOSPHATE; N ACETYLGALACTOSAMINE 4 SULFATASE; SOMATOMEDIN B RECEPTOR;

ANTIBODY TITER; CARTILAGE CELL; DOG; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEFICIENCY; ENZYME KINETICS; ENZYME REPLACEMENT; EXPERIMENTAL MOUSE; FABRY DISEASE; FIBROBLAST; GAUCHER DISEASE; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; HEART MUSCLE CELL; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; KIDNEY CELL; KIDNEY TUBULE CELL; LIVER CELL; LYSOSOME STORAGE DISEASE; MACROPHAGE; MAROTEAUX LAMY SYNDROME; NERVE CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SPLEEN CELL; TARGET CELL; TRANSPORT KINETICS;

ANIMALS; ANTIBODIES; AZATHIOPRINE; CYCLOSPORINE; DOGS; IDURONIDASE; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LYSOSOMAL STORAGE DISEASES; MODELS, IMMUNOLOGICAL; MUCOPOLYSACCHARIDOSIS I; TIME FACTORS;

EID: 48749084652     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36521     Document Type: Note

References (20)

1. Fakharzadeh, S.S., and Kazazian, H.H., Jr. 2000. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost. 26:167-171.
2. Dickson, P., et al. 2008. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J. Clin. Invest. 118:2868-2876.
3. Barton, N.W., et al. 1991. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324:1464-1470.
4. Starzyk, K., Richards, S., Yee, J., Smith, S.E., and Kingma, W. 2007. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol. Genet. Metab. 90:157-163.
5. Rohrbach, M., and Clarke, J.T. 2007. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs. 67:2697-2716.
6. Kakkis, E.D., et al. 2001. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344:182-188.
7. Wraith, J.E., et al. 2007 Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 120:e37-e46.
8. Shull, R.M., et al. 1994. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. U. S. A. 91:12937-12941.
9. Kakkis, E.D., et al. 1996. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Molec. Med. 58:156-167.
10. Kakkis, E., et al. 2004. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc. Natl. Acad. Sci. U. S. A. 101:829-834.
11. Gao, W., et al. 2007. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am. J. Transplant. 7:1722-1732.
12. Lim, D.G., et al. 2007. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl. Immunol. 18:94-100.
13. Adams, A.B., Pearson, T.C., and Larsen, C.P. 2001. Conventional immunosuppression and co-stimulation blockade. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:703-705.
14. San Segundo, D., Fábrega, E., López-Hoyos, M., and Pons, F. 2007. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc. 39:2290-2292.
15. Tiede, I., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111:1133-1145.
16. Joseph, A., Munroe, K., Housman, M., Garman, R., and Richards, S. 2008. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152:138-146.
17. Turner, C.T., Hopwood, J.J., Bond, C.S., and Brooks, D.A. 1999. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats. Mol. Genet. Metab. 67:194-205.
18. Sun, B., Bird, A., Young, S.P., Kishnani, P.S., Chen, Y.T., and Koeberl, D.D. 2007. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am. J. Hum. Genet. 81:1042-1049.
19. Kishnani, P.S., et al. 2007. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 68:99-109.
20. Ohashi, T., Iizuka, S., Ida, H., and Eto, Y. 2008. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol. Genet. Metab. 94:313-318.